What is Potentilla erecta used for?

Potentilla erecta (tormentil) is primarily used for symptomatic relief of mild, non-infectious diarrhea and for soothing inflammation of the mouth and throat mucosa. Its use is recognized in the German Commission E and ESCOP monographs, though clinical trial evidence remains limited to small pilot studies rather than large randomized controlled trials.

What is the active compound in Potentilla erecta?

The key bioactive compounds are ellagitannins—specifically tormentillin, potentillin, and agrimoniin—concentrated in the rhizome, which typically contains 15–22% total tannins by dry weight. These tannins are responsible for both the astringent effect on mucosal membranes and the inhibition of prostaglandin biosynthesis observed in vitro.

What is the recommended dosage of Potentilla erecta?

Traditional and pharmacopoeial recommendations generally suggest 3–6 g of dried tormentil rhizome per day as a decoction, or 1–2 g of a standardized dry extract (typically standardized to tannin content). For oral rinses targeting mouth and throat inflammation, a decoction prepared from 2–3 g in 150 mL water used several times daily is commonly referenced in European herbal monographs.

Does Potentilla erecta interact with any medications?

The high tannin content can form insoluble complexes with oral iron supplements, reducing iron absorption by an estimated 50–70% when taken simultaneously—a two-hour separation window is advised. Tannins may also bind to and reduce bioavailability of alkaloid-based drugs and certain broad-spectrum antibiotics; however, formal pharmacokinetic interaction studies in humans are absent from the published literature.

Is Potentilla erecta safe for children?

One small RCT (n=40) evaluated tormentil root extract in children aged 3 months to 5 years with rotavirus diarrhea, finding a reduction in diarrhea duration by approximately one day compared to placebo with no serious adverse events reported. However, given the limited safety data in pediatric populations and the absence of dose-ranging studies in children, use in infants and young children should only occur under medical supervision.

Who should avoid Potentilla erecta due to its tannin content?

Individuals with sensitive digestion, iron deficiency anemia, or those taking iron supplements should exercise caution, as high tannin content can inhibit mineral absorption and may cause gastrointestinal irritation in susceptible persons. People with severe constipation should avoid Potentilla erecta due to its astringent properties, which could worsen the condition. Those with known allergies to Rosaceae family plants should consult a healthcare provider before use.

What is the difference between using Potentilla erecta as a tea versus other forms?

Potentilla erecta is traditionally prepared as a decoction or tea to extract its tannin compounds and astringent properties for oral and throat use. Standardized extracts or supplements may concentrate active constituents, though comparative bioavailability data between traditional tea preparation and modern formulations is limited. The decoction method has centuries of traditional use documentation, whereas newer supplement forms lack the same historical evidence base for efficacy.

Potentilla erecta

Potentilla erecta (tormentil) is a medicinal herb whose primary bioactive compounds, ellagitannins including tormentillin and agrimoniin, exert astringent and anti-inflammatory effects by precipitating proteins on mucosal surfaces and inhibiting prostaglandin biosynthesis. It has been used for centuries in European folk medicine and is included in several national pharmacopoeias for the symptomatic relief of mild diarrhea and oral inflammation.

Category: European Evidence: 2/10 Tier: Traditional

Potentilla erecta — Hermetica Encyclopedia

Origin & History

Potentilla erecta (tormentil) is a perennial herbaceous plant in the Rosaceae family, native to Eurasia and found in bogs, heaths, moors, and alpine slopes. The medicinal part is the dried rhizome (Tormentillae rhizoma), harvested from wild plants and used as comminuted herbal substance or in traditional infusions.

Historical & Cultural Context

Potentilla erecta has been used in European folk medicine for over 500 years, documented from medieval herbal books to present day. Traditional applications included treatment of inflammatory states, wounds, mild diarrhea, dysentery, and dysmenorrhea across Germany, Italy, Sweden, and Russia.

Health Benefits

• Traditional use for mild diarrhea (based on 500+ years of folk medicine, no clinical trials available)
• Traditional use for mild inflammation of mouth and throat mucosa (historical evidence only, no RCTs)
• In vitro anti-inflammatory effects through inhibition of prostaglandin biosynthesis (laboratory studies only)
• Traditional astringent properties attributed to high tannin content (no human clinical validation)
• Historical use for supportive therapy in gastrointestinal complaints (traditional evidence only)

How It Works

The ellagitannins in Potentilla erecta, particularly tormentillin, potentillin, and agrimoniin, bind to and precipitate surface proteins on mucosal membranes, forming a protective layer that reduces fluid secretion and microbial adhesion—the primary astringent mechanism underlying anti-diarrheal effects. These tannins also inhibit cyclooxygenase (COX) enzymes, reducing prostaglandin E2 (PGE2) biosynthesis in vitro, which accounts for the observed anti-inflammatory activity. Additionally, proanthocyanidins present in the root may scavenge reactive oxygen species (ROS) and modulate NF-κB signaling, further contributing to localized anti-inflammatory effects on irritated mucosal tissue.

Scientific Research

No clinical trials, RCTs, or meta-analyses with PubMed PMIDs are available for Potentilla erecta. The EMA HMPC classifies it for traditional use only due to insufficient clinical evidence, with ESCOP and HMPC noting a complete lack of convincing human studies meeting modern standards.

Clinical Summary

Clinical evidence for Potentilla erecta remains sparse; one small randomized controlled trial in children with rotavirus diarrhea (n=40) reported a statistically significant reduction in diarrhea duration compared to placebo, but the study was limited by small sample size and single-center design. A pilot study in adults with mild inflammatory bowel conditions suggested symptomatic improvement, but lacked a control group and used heterogeneous endpoints. The majority of support derives from pharmacopoeial monographs (ESCOP, German Commission E) granting traditional-use status based on documented historical application exceeding 30 years, rather than from prospective RCTs. Overall, the evidence is rated as low quality by modern EBM standards, and no large-scale phase III trials have been conducted.

Nutritional Profile

Potentilla erecta (tormentil) is a medicinal herb, not a food ingredient, so macronutrient and caloric profiling is not applicable in conventional nutritional terms. Its bioactive composition is well-characterized phytochemically: PRIMARY BIOACTIVE COMPOUNDS: Hydrolyzable tannins are the dominant constituents, comprising 15–22% dry weight of the rhizome, primarily agrimoniin (an ellagitannin, ~8–12% dry weight), pedunculagin, and potentillin. Condensed tannins (proanthocyanidins) are also present at approximately 2–5% dry weight. PHENOLIC COMPOUNDS: Ellagic acid and gallic acid are present as hydrolysis products of the tannins; ellagic acid concentration estimated at 0.5–2% dry weight post-hydrolysis. Catechins and epicatechins present in minor quantities (<1%). TRITERPENOIDS: Tormentoside (a triterpenoid glycoside), ursolic acid, oleanolic acid, and pomolic acid identified; total triterpenoid content approximately 0.5–1.5% dry weight. FLAVONOIDS: Quercetin, kaempferol, and their glycosides present at low concentrations (<0.5% dry weight collectively). PHLOBAPHENES: Red pigment compounds (tormentil red) resulting from tannin oxidation, qualitatively identified. MINOR CONSTITUENTS: Trace volatile oils, resins, and starch in rhizome tissue. MACRONUTRIENTS: Negligible protein (<5% dry weight, non-nutritionally relevant), carbohydrates present primarily as structural polysaccharides and starch (~30–40% dry weight of rhizome), lipid content minimal (<1%). VITAMINS/MINERALS: No significant vitamin content documented; mineral data sparse, with trace calcium and potassium expected but not quantified in literature. BIOAVAILABILITY NOTES: Tannin bioavailability is inherently limited due to their large molecular weight and protein-binding capacity; ellagic acid undergoes gut microbiota conversion to urolithins (urolithin A, B), which may represent the systemically active metabolites. Tannin-protein binding in the gut reduces absorption but confers local astringent effects on mucosa, which is mechanistically consistent with its traditional gastrointestinal applications. Data derives primarily from phytochemical analyses of European-sourced rhizomes; standardization in commercial preparations typically targets 17–20% tannin content.

Preparation & Dosage

Traditional oral use (adults/elderly): Comminuted herbal substance as infusion, 1.4-4 g per single dose, several times daily, maximum 12 g daily. No clinically studied dosages exist for extracts or standardized forms. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Oak bark, Chamomile, Marshmallow root, Slippery elm, Plantain

Safety & Interactions

Potentilla erecta is generally well tolerated at typical doses (3–6 g of dried root daily or equivalent extract); the high tannin content may cause mild gastrointestinal upset, nausea, or constipation in sensitive individuals. Due to tannin-mediated protein binding, concurrent oral administration may reduce the absorption of iron supplements, alkaloid-based medications, and certain antibiotics—separation by at least two hours is recommended. No well-documented drug–drug interactions with anticoagulants or CYP450-metabolized drugs have been established, but caution is advised given the lack of pharmacokinetic interaction studies. Safety during pregnancy and lactation has not been established in clinical trials, and use is not recommended during these periods based on precautionary principles.